Global Bispecific Antibodies Market Size Study & Forecast, by Indication (Cancer, Inflammatory & Autoimmune Disorders, Others), and Regional Analysis, 2023-2030

Global Bispecific Antibodies Market Size Study & Forecast, by Indication (Cancer, Inflammatory & Autoimmune Disorders, Others), and Regional Analysis, 2023-2030

Global Bispecific Antibodies Market is valued at approximately USD 5.73 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 44.0% over the forecast period 2023-2030. Bispecific antibodies are a class of therapeutic proteins created to attach to two distinct target molecules simultaneously. These antibodies have two separate antigen-binding sites that recognize a different antigen or receptor because of genetic engineering. Bispecific antibodies assemble these molecules, control their interactions, or transport medicinal substances to body parts by attaching two distinct targets. Bispecific antibodies provide several benefits compared to conventional monoclonal antibodies, which normally bind to a single target. They are used to target numerous disease-related pathways concurrently or to divert immune cells away from healthy tissue and toward tumor cells. The growing demand for targeted and personalized therapies, significant advancements in antibody engineering technologies, along with increasing collaborations and partnerships between local and international stakeholders are the key factors that are propelling the market demand during the estimated period.

In addition, the surge in the incidences of cancer cases is fueling the demand for a range of treatment alternatives including biospecific antibodies particularly those designed as immune checkpoint inhibitors or T cell engagers, which, in turn, accelerating the market growth across the world. According to The Global Cancer Observatory (GCO), in 2020, about 19.3 million new cases of cancer were reported worldwide and this number is expected to increase to 30.2 million in the year 2040. Biospecific antibodies redirect immune cells to attack tumor cells, leading to tumor regression and improved patient outcomes. Moreover, the increasing investment in biologics research and development, as well as the robust growth of the biopharmaceutical pipeline present various lucrative opportunities over the forecast years. However, the complex development and manufacturing and regulatory challenges are challenging the market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Bispecific Antibodies Market study include Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the increasing approval for several bispecific antibodies by regulatory bodies, growing investment in R&D activities, along with the presence of several leading market players. For instance, in October 2022, the first bispecific B-cell maturation antigen, teclistamab-cqyv (Tecvayli, Janssen Biotech, Inc.), received FDA approval. In addition, companies are increasingly participating in partnerships and collaborations to use complementary scientific expertise and technology to create bispecific antibodies. These partnerships promoted research and development initiatives, which has further accelerated market expansion. Europe is expected to grow at a substantial CAGR over the forecast years. The surging demand for bispecific antibodies, rising focus on technological advancements, as well as increasing collaborations and partnerships between local and international stakeholders are significantly propelling the market demand across the region.

Major market players included in this report are:
Amgen, Inc.
Bayer AG
Dow Pharmaceutical Solutions
ImmunGene, Inc.
Immunocore Limited
Merck & Co., Inc.
Novartis AG
Pfizer, Inc.
F. Hoffmann-La Roche AG
Akeso, Inc.

Recent Developments in the Market:
In January 2023, Genentech, Inc., an American biotechnology corporation announced that the company has received FDA approval for the company’s bispecific antibody that is specially designed for lymphoma. This approval enables the company to market their bispecific antibody across the region.
In May 2023, Genmab A/S unveiled that the U.S. Food and Drug Administration (FDA) has approved EPKINL (epcoritamab-bysp) as the first and only T-cell engaging bispecific antibody for the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS), including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma, following two or more lines of systemic therapy.

Global Bispecific Antibodies Market Report Scope:
Historical Data – 2020 - 2021
Base Year for Estimation – 2022
Forecast period - 2023-2030
Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered - Indication, Region
Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.

The detailed segments and sub-segment of the market are explained below:

By Indication:
Cancer
Inflammatory & Autoimmune Disorders
Others

By Region:

North America
U.S.
Canada

Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC

Latin America
Brazil
Mexico

Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa



Companies Mentioned
Amgen, Inc.
Bayer AG
Dow Pharmaceutical Solutions
ImmunGene, Inc.
Immunocore Limited
Merck & Co., Inc.
Novartis AG
Pfizer, Inc.
F. Hoffmann-La Roche AG
Akeso, Inc.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.